#1 Clinical Trials Search in Europe

Citalopram Hydrochloride

This article explores the use of Citalopram Hydrochloride in clinical trials for two distinct medical conditions: gastroesophageal reflux disease (GERD) and major depressive disorder (MDD). We’ll examine how this medication is being studied to potentially improve symptoms in both digestive and mental health contexts, highlighting the versatility of pharmaceutical research in addressing diverse health concerns.

Table of Contents

What is Citalopram Hydrochloride?

Citalopram Hydrochloride, often referred to simply as Citalopram, is a medication that belongs to a class of drugs called Selective Serotonin Reuptake Inhibitors (SSRIs). SSRIs work by increasing the levels of a neurotransmitter called serotonin in the brain, which is believed to help regulate mood and emotions[2].

Medical Conditions Treated with Citalopram

Citalopram is primarily used to treat the following conditions:

  • Major Depressive Disorder (MDD): This is a serious mental health condition characterized by persistent feelings of sadness, hopelessness, and loss of interest in activities[2].
  • Gastro-Esophageal Reflux Disease (GERD): Although not its primary use, some research suggests that Citalopram may have potential benefits in treating GERD, a condition where stomach acid frequently flows back into the esophagus[1].

How Citalopram is Administered

Citalopram can be administered in different ways, depending on the specific treatment and research protocol:

  • Oral tablets: This is the most common form for regular, long-term use.
  • Intravenous (IV) infusion: In some research studies, Citalopram is administered intravenously. For example, one study used a dose of 40 mg of Citalopram diluted in 60 cc of normal saline, delivered over a 40-minute period[2].

Current Research Studies

Citalopram is currently being studied for its effects on various conditions:

  • GERD Treatment: Researchers are investigating whether Citalopram can affect the lower esophageal sphincter pressure, transient lower esophageal sphincter relaxations, and reflux episodes in patients with GERD[1].
  • Depression Treatment in Combination with TMS: A study is exploring the effects of intravenous Citalopram when combined with Transcranial Magnetic Stimulation (TMS), a non-invasive brain stimulation technique, for treating Major Depressive Disorder[2].

Potential Side Effects and Monitoring

While Citalopram is generally considered safe, it can cause side effects. In clinical trials, the following monitoring procedures were implemented:

  • Vital sign monitoring: This includes blood pressure, pulse oximetry (measuring oxygen levels in the blood), and respiratory rate recording[2].
  • Mental status monitoring: To assess for any undesired behavioral or psychological effects[2].

Patients should be aware of potential side effects and report any unusual symptoms to their healthcare provider.

Effectiveness and Treatment Outcomes

The effectiveness of Citalopram is typically measured using standardized assessment tools:

  • Hamilton Depression Rating Scale (Ham-D17): This 17-item scale is used to assess the severity of depression symptoms. Scores of 0-7 are considered normal, 8-16 suggest mild depression, 17-23 moderate depression, and scores over 24 indicate severe depression[2].
  • Inventory of Depressive Symptomatology-Self Report (IDS-SR): This 30-item self-report questionnaire is designed to assess the severity of depressive symptoms over the past seven days[2].

Treatment success is often defined as a 50% or greater improvement from baseline on the Ham-D17, with remission considered as a final Ham-D17 score less than 7[2].

Aspect Reflux Study Depression Study
Condition Gastroesophageal Reflux Major Depressive Disorder
Participants Healthy Volunteers Patients with MDD
Citalopram Dose 20 mg, IV 40 mg, IV
Additional Intervention None Transcranial Magnetic Stimulation
Primary Measurements LES pressure, reflux episodes, TLESRs Changes in depression symptoms, brain activity
Measurement Techniques High-resolution impedance manometry EEG, MRI, fMRI, mood surveys
Study Duration Single session 4 weeks

FAQ

  • What is Citalopram Hydrochloride? Citalopram Hydrochloride is a medication primarily known as an antidepressant. It belongs to a class of drugs called selective serotonin reuptake inhibitors (SSRIs). In these clinical trials, it's being studied for its potential effects on both gastroesophageal reflux and major depressive disorder.
  • How is Citalopram being studied for reflux? In one trial, researchers are investigating if Citalopram can affect the lower esophageal sphincter pressure, transient lower esophageal sphincter relaxations, and reflux episodes. They're using high-resolution impedance manometry to measure these effects in healthy volunteers before and after a meal.
  • What is the purpose of using Citalopram in the depression study? In the depression study, intravenous Citalopram is being used alongside a brain stimulation technique called transcranial magnetic stimulation (TMS). Researchers are looking at how Citalopram might influence brain activity and connectivity when combined with TMS in people with major depressive disorder.
  • What are the main differences between the two trials? The reflux study focuses on Citalopram's potential effects on the digestive system in healthy volunteers, while the depression study examines its impact on brain function in people with major depressive disorder. The reflux study uses a single dose, while the depression study combines Citalopram with repeated TMS treatments.
  • How are the effects of Citalopram measured in these trials? In the reflux study, effects are measured using high-resolution impedance manometry to assess esophageal function. In the depression study, researchers use brain scans (MRI and fMRI), brain activity recordings (EEG), and mood surveys to evaluate the effects of Citalopram combined with TMS.

Ongoing Clinical Trials on Citalopram Hydrochloride

  • Safe Discontinuation of Antidepressants in Patients with Remitted Depression: Amitriptyline, Fluoxetine, Paroxetine, and Drug Combination Study

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • Citalopram Hydrochloride: An antidepressant medication belonging to the selective serotonin reuptake inhibitor (SSRI) class, being studied for its potential effects on both gastroesophageal reflux and major depressive disorder.
  • Gastroesophageal Reflux: A condition where stomach contents flow back into the esophagus, potentially causing discomfort and other symptoms.
  • Lower Esophageal Sphincter (LES): A ring of muscle that acts as a valve between the esophagus and stomach, helping to prevent reflux.
  • Transient Lower Esophageal Sphincter Relaxations (TLESRs): Temporary relaxations of the lower esophageal sphincter that are not related to swallowing, which can lead to reflux episodes.
  • High Resolution Impedance Manometry: A diagnostic technique used to measure pressure and movement in the esophagus and its sphincters.
  • Major Depressive Disorder (MDD): A mental health condition characterized by persistent feelings of sadness, hopelessness, and loss of interest in activities, affecting a person's thoughts, emotions, and behaviors.
  • Transcranial Magnetic Stimulation (TMS): A non-invasive brain stimulation technique that uses magnetic fields to stimulate specific areas of the brain, often used in treating depression.
  • Theta Burst Stimulation (TBS): A form of TMS that delivers rapid bursts of magnetic pulses, potentially producing longer-lasting effects on brain activity.
  • Electroencephalography (EEG): A method to record electrical activity in the brain using electrodes placed on the scalp.
  • Functional Magnetic Resonance Imaging (fMRI): A neuroimaging technique that measures brain activity by detecting changes in blood flow.

References

  1. https://clinicaltrials.gov/study/NCT03746691
  2. https://clinicaltrials.gov/study/NCT04846829